Active Targeting Significantly Outperforms Nanoparticle Size in Facilitating Tumor-Specific Uptake in Orthotopic Pancreatic Cancer
Source abstract
Abstract
Nanoparticles are widely studied as theranostic vehicles for cancer; however, clinical translation has been limited due to poor tumor specificity. Features that maximize tumor uptake remain controversial, particularly when using clinically relevant models. We report a systematic study that assesses two major features for the impact on tumor specificity, i.e., active vs passive targeting and nanoparticle size, to evaluate relative influences in vivo. Active targeting via the V7 peptide is superior to passive targeting for uptake by pancreatic tumors, irrespective of nanoparticle size, observed through in vivo imaging. Size has a secondary effect on uptake for actively targeted nanoparticles in which 26 nm nanoparticles outperform larger 45 and 73 nm nanoparticles. Nanoparticle size had no significant effect on uptake for passively targeted nanoparticles. Results highlight the superiority of active targeting over nanoparticle size for tumor uptake. These findings suggest a framework for optimizing similar nonaggregate nanoparticles for theranostic treatment of recalcitrant cancers.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Cancer Research and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Stephenson Cancer Center, University of Oklahoma, Oklahoma City, Oklahoma 73104, United States
Department of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma 73019, United States
Department of Surgery, University of Oklahoma, Oklahoma City, Oklahoma 73104, United States
Department of Cancer Biology, Wake Forest University, Winston-Salem, North Carolina 27157, United States
Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama 35294, United States
Department of Surgery, University of Louisville, Louisville, Kentucky 40202, United States
Conn Center Materials Characterization, University of Louisville, Louisville, Kentucky 40202, United States
Department of Mechanical Engineering, Virginia Tech, Blacksburg, Virginia 24061, United States
Funding
U.S. Department of Health and Human Services
References (81)
Show source-provided references
1. 10.1038/s41565-020-0759-510.1038/s41565-020-0759-5 ↗
2. 10.1021/nn500299p10.1021/nn500299p ↗
3. 10.1371/journal.pone.005687610.1371/journal.pone.0056876 ↗
4. 10.1016/j.addr.2013.11.00910.1016/j.addr.2013.11.009 ↗
5. 10.1021/acs.nanolett.7b0002110.1021/acs.nanolett.7b00021 ↗
6. 10.1126/sciadv.aay160110.1126/sciadv.aay1601 ↗
7. Haubner R. · J. Nucl. Med. · 2001 · 42 · 326
8. 10.1016/j.biomaterials.2013.02.01410.1016/j.biomaterials.2013.02.014 ↗
9. 10.1038/onc.2014.29110.1038/onc.2014.291 ↗
10. 10.1158/1078-0432.CCR-15-031410.1158/1078-0432.CCR-15-0314 ↗
11. 10.1038/nrc329810.1038/nrc3298 ↗
12. 10.1073/pnas.130370811010.1073/pnas.1303708110 ↗
13. 10.3389/fphys.2014.0009710.3389/fphys.2014.00097 ↗
14. 10.3109/09687688.2010.50928510.3109/09687688.2010.509285 ↗
15. 10.1073/pnas.080474610510.1073/pnas.0804746105 ↗
16. 10.3389/fchem.2020.0070310.3389/fchem.2020.00703 ↗
17. 10.1016/j.colsurfb.2012.11.01910.1016/j.colsurfb.2012.11.019 ↗
18. 10.1016/j.ijpharm.2018.10.01110.1016/j.ijpharm.2018.10.011 ↗
19. 10.1038/nbt.333010.1038/nbt.3330 ↗
20. 10.2147/IJN.S2659210.2147/IJN.S26592 ↗
21. 10.1038/nnano.2011.16610.1038/nnano.2011.166 ↗
22. 10.4103/2230-973X.16084410.4103/2230-973X.160844 ↗
23. 10.3390/pharmaceutics1003011810.3390/pharmaceutics10030118 ↗
24. 10.1038/nature0887810.1038/nature08878 ↗
25. 10.1039/c0jm04115g10.1039/c0jm04115g ↗
26. 10.1002/ange.20110476510.1002/ange.201104765 ↗
27. 10.1007/s10856-011-4397-110.1007/s10856-011-4397-1 ↗
28. 10.1186/1477-3155-12-510.1186/1477-3155-12-5 ↗
29. 10.1002/wnan.16510.1002/wnan.165 ↗
30. 10.4155/tde.12.910.4155/tde.12.9 ↗
31. 10.1016/j.micromeso.2016.08.03810.1016/j.micromeso.2016.08.038 ↗
32. 10.1016/j.jconrel.2015.12.05510.1016/j.jconrel.2015.12.055 ↗
33. 10.1016/j.addr.2012.07.01810.1016/j.addr.2012.07.018 ↗
34. 10.1039/C7CS00219J10.1039/C7CS00219J ↗
35. 10.1186/s11671-017-1853-y10.1186/s11671-017-1853-y ↗
36. 10.1021/mp900022m10.1021/mp900022m ↗
37. 10.1158/1078-0432.CCR-16-057310.1158/1078-0432.CCR-16-0573 ↗
38. 10.1126/scitranslmed.aad127810.1126/scitranslmed.aad1278 ↗
39. 10.1056/NEJMc161245510.1056/NEJMc1612455 ↗
40. 10.1148/rycan.202020006610.1148/rycan.2020200066 ↗
41. 10.1016/j.pacs.2018.11.00310.1016/j.pacs.2018.11.003 ↗
42. 10.1016/j.msec.2019.01.06610.1016/j.msec.2019.01.066 ↗
43. 10.1016/j.jss.2014.06.04510.1016/j.jss.2014.06.045 ↗
44. 10.1021/acsbiomaterials.6b0011110.1021/acsbiomaterials.6b00111 ↗
45. 10.2217/17435889.3.4.57910.2217/17435889.3.4.579 ↗
46. 10.1364/OL.39.00406110.1364/OL.39.004061 ↗
47. 10.1080/10520295.2016.125161110.1080/10520295.2016.1251611 ↗
48. 10.1002/smll.20090000510.1002/smll.200900005 ↗
49. 10.1038/nnano.2012.4510.1038/nnano.2012.45 ↗
50. 10.1186/1743-8977-4-1010.1186/1743-8977-4-10 ↗
51. 10.1016/j.ccr.2007.04.01810.1016/j.ccr.2007.04.018 ↗
52. 10.1016/S0169-409X(98)00006-410.1016/S0169-409X(98)00006-4 ↗
53. 10.1016/j.ejpb.2007.08.00110.1016/j.ejpb.2007.08.001 ↗
54. 10.1021/cm300168810.1021/cm3001688 ↗
55. 10.1039/b908625k10.1039/b908625k ↗
56. 10.1021/la046829z10.1021/la046829z ↗
57. 10.1039/C5EN00179J10.1039/C5EN00179J ↗
58. 10.1007/s10555-007-9064-010.1007/s10555-007-9064-0 ↗
59. Cruz-Monserrate Z. · Sci. Rep. · 2015 · 4 · 1
60. 10.2967/jnumed.109.06898110.2967/jnumed.109.068981 ↗
61. 10.1073/pnas.070243910410.1073/pnas.0702439104 ↗
62. 10.1186/s12951-015-0139-810.1186/s12951-015-0139-8 ↗
63. 10.1016/j.biomaterials.2018.08.00110.1016/j.biomaterials.2018.08.001 ↗
64. 10.1016/j.jconrel.2013.09.01310.1016/j.jconrel.2013.09.013 ↗
65. 10.1021/mp800049w10.1021/mp800049w ↗
66. 10.1038/s41563-020-0755-z10.1038/s41563-020-0755-z ↗
67. 10.1016/j.addr.2010.03.01110.1016/j.addr.2010.03.011 ↗
68. 10.1016/0026-2862(89)90074-510.1016/0026-2862(89)90074-5 ↗
69. 10.2217/17435889.3.5.70310.2217/17435889.3.5.703 ↗
70. 10.2147/IJN.S2165710.2147/IJN.S21657 ↗
71. 10.1186/s13223-019-0327-410.1186/s13223-019-0327-4 ↗
72. 10.14309/crj.2015.6310.14309/crj.2015.63 ↗
73. 10.1186/s13223-016-0172-710.1186/s13223-016-0172-7 ↗
74. 10.1016/j.addr.2010.09.00110.1016/j.addr.2010.09.001 ↗
75. 10.1038/s41598-017-10836-710.1038/s41598-017-10836-7 ↗
76. 10.1039/C9AN01056D10.1039/C9AN01056D ↗
77. 10.1016/S1748-0132(08)70014-810.1016/S1748-0132(08)70014-8 ↗
78. 10.3390/pharmaceutics1304057010.3390/pharmaceutics13040570 ↗
79. 10.1002/ange.20130446510.1002/ange.201304465 ↗
80. 10.1016/j.pacs.2014.06.00110.1016/j.pacs.2014.06.001 ↗
81. 10.1016/j.pacs.2018.07.00310.1016/j.pacs.2018.07.003 ↗